Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome

S. Heymann1, Suzette Delaloge2, Arslane Skander Rahal2, Olivier Caron3, Thierry Frébourg4, L. Barreau5, C. Pachet5, Marie‐Christine Mathieu6, H. Marsiglia7, C. Bourgier1
1Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
2Department of Breast Oncology, Institut Gustave Roussy, Villejuif, France
3Department of Genetics Counseling, Institut Gustave Roussy, Villejuif, France
4Genetic Department, Academic Hospital, Rouen, France
5Department of Breast Surgery, Institut Gustave Roussy, Villejuif, France
6Department of Pathology, Institut Gustave Roussy, Villejuif, France
7University of Florence, University of Florence, Italy

Tóm tắt

Từ khóa


Tài liệu tham khảo

Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969, 71: 747-752.

Gonzalez KD, Noltner KA, Buzin CH, et al.: Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009, 27: 1250-1256. 10.1200/JCO.2008.16.6959

Li FP, Fraumeni JF Jr, Mulvihill JJ, et al.: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48: 5358-5362.

Varley JM: Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003, 21: 313-320. 10.1002/humu.10185

Olivier M, Goldgar DE, Sodha N, et al.: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003, 63: 6643-6650.

Lee SB, Kim SH, Bell DW, et al.: Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res 2001, 61: 8062-8067.

Varley J: TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol 2003, 222: 117-129.

Varley J, Haber DA: Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res 2003, 5: 123-125. 10.1186/bcr582

Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408: 307-310. 10.1038/35042675

Vousden KH: Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 2002, 1602: 47-59.

Gasco M, Shami S, Crook T: The p53 pathway in breast cancer. Breast Cancer Res 2002, 4: 70-76. 10.1186/bcr426

Wang QE, Zhu Q, Wani MA, et al.: Tumor suppressor p53 dependent recruitment of nucleotide excision repair factors XPC and TFIIH to DNA damage. DNA Repair (Amst) 2003, 2: 483-499. 10.1016/S1568-7864(03)00002-8

Fei P, El-Deiry WS: P53 and radiation responses. Oncogene 2003, 22: 5774-5783. 10.1038/sj.onc.1206677

Bougeard G, Brugieres L, Chompret A, et al.: Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene 2003, 22: 840-846. 10.1038/sj.onc.1206155

Kony SJ, de Vathaire F, Chompret A, et al.: Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 1997, 350: 91-95. 10.1016/S0140-6736(97)01116-1

Hisada M, Garber JE, Fung CY, et al.: Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998, 90: 606-611. 10.1093/jnci/90.8.606

Nutting C, Camplejohn RS, Gilchrist R, et al.: A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 2000, 12: 300-304.

Limacher JM, Frebourg T, Natarajan-Ame S, et al.: Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001, 96: 238-242. 10.1002/ijc.1021

Salmon A, Amikam D, Sodha N, et al.: Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol) 2007, 19: 490-493.

Bollet MA, Sigal-Zafrani B, Mazeau V, et al.: Age remains the first prognostic factor for loco-regional breast cancer recurrence in young ( < 40 years) women treated with breast conserving surgery first. Radiother Oncol 2007, 82: 272-280. 10.1016/j.radonc.2007.01.001

Prise en charge du cancer du sein infiltrant de la femme non ménopausée Oncologie 2009, 11: 507-532. 10.1007/s10269-009-1818-6

Livasy CA, Karaca G, Nanda R, et al.: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19: 264-271. 10.1038/modpathol.3800528

Veronesi U, Marubini E, Del Vecchio M, et al.: Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995, 87: 19-27. 10.1093/jnci/87.1.19

Fowble BL, Schultz DJ, Overmoyer B, et al.: The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994, 30: 23-33.

Rubino C, de Vathaire F, Shamsaldin A, et al.: Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 2003, 89: 840-846. 10.1038/sj.bjc.6601138

Delia D, Goi K, Mizutani S, et al.: Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene 1997, 14: 2137-2147. 10.1038/sj.onc.1201050

Mitchel RE, Jackson JS, Carlisle SM: Upper dose thresholds for radiation-induced adaptive response against cancer in high-dose-exposed, cancer-prone, radiation-sensitive Trp53 heterozygous mice. Radiat Res 2004, 162: 20-30. 10.1667/RR3190

Tinat J, Bougeard G, Baert-Desurmont S, et al.: 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009, 27: e108-109. author reply e110 10.1200/JCO.2009.22.7967